- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

Eye-safe laser technology to diagnose traumatic brain injury

Researchers from the University of Birmingham have designed and developed a novel diagnostic device to detect traumatic brain injury (TBI) by shining a safe...
- Advertisement -
- Advertisement -
- Advertisement -

Tech-enabled pharma marketing strategies

Palm trees bend and sway in hurricane-force winds that could topple an oak or...

Brand planning for pharma companies

As the Health and Care Bill begins its journey through parliament, how will structural...

Perspectives across the Breast Continuum of Care

Many healthcare professionals (HCPs) play an imperative role in the breast cancer pathway, and none work in isolation. It is essential that there is...

Q&A: Brand optimisation – Maximising pharma’s commercial impact

Intro: It’s not too late to close out 2023 with a bang. Pharma can capitalise on the remainder of the year and prep for...

Delivering equity in women’s health: How can pharma help turn this into a reality?

A year on from the publication of the first Women's Health Strategy, Doina Ionescu, General Manager, Merck UK and RoI, examines the progress made...

Subscribe for FREE

View all issues

- Advertisement -
- Advertisement -

The Trust Equation: how to transform partnerships

Fiona Bride, Director of Market Access, Novartis Pharmaceuticals UK, examines how bold partnerships can help the NHS overcome the challenges it faces. The past two...

Janssen seeks approval for its multiple myeloma treatment

Janssen has announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of talquetamab for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Talquetamab is an investigational, off-the-shelf (ready to...

Bristol Myers Squibb appoints new Senior Vice President and Head of Major Markets

Bristol Myers Squibb has announced that Dr Monica Shaw joins the company’s commercial leadership...

Pheon Therapeutics appoints new CEO

Pheon Therapeutics, an Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide...

Destiny Pharma appoints new CEO

Destiny Pharma, a clinical stage innovative biotechnology company focused on the development of novel...


View all roles


On demand: Maximising pharma’s commercial impact with brand optimisation

Uniphar’s Client Solutions Director, Mark Ward, and Director of Consulting, Nick Bartlett, chair a Pf Media and Uniphar webinar, ‘Maximising pharma’s commercial impact with...


Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription